Shares of Freenome (NASDAQ:FRNM – Get Free Report) have earned an average rating of “Moderate Buy” from the six analysts that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $18.00.
Several research firms have recently commented on FRNM. Leerink Partners initiated coverage on shares of Freenome in a research report on Friday, August 14th. They set an “outperform” rating and a $18.00 price target for the company. Wall Street Zen upgraded shares of Freenome to a “sell” rating in a research note on Saturday, September 26th. BTIG Research assumed coverage on shares of Freenome in a report on Monday, August 17th. They issued a “buy” rating and a $17.00 price objective on the stock. Guggenheim assumed coverage on shares of Freenome in a research report on Thursday, August 20th. They set a “buy” rating and a $21.00 target price for the company. Finally, TD Cowen started coverage on shares of Freenome in a research report on Tuesday, August 18th. They set a “buy” rating and a $17.00 target price for the company.
Read Our Latest Research Report on Freenome
Freenome Price Performance
Shares of NASDAQ:FRNM opened at $10.18 on Friday. The stock has a market capitalization of $1.09 billion, a PE ratio of -169.64 and a beta of 0.60. The stock has a 50-day moving average price of $14.44. Freenome has a 52-week low of $9.71 and a 52-week high of $17.50.
Freenome Company Profile
Freenome is a biotechnology company developing blood-based tests designed to detect cancer at an early stage. Its platform combines artificial intelligence with multiomics, including genomic, epigenomic and proteomic signals found in blood, to identify patterns associated with cancer.
The company has focused its research and clinical development efforts on screening for colorectal cancer and other common cancers. Freenome’s products are intended to support noninvasive screening and may complement or provide an alternative to certain conventional screening methods, subject to regulatory review and approval.
Founded in 2014, Freenome is headquartered in South San Francisco, California.
Featured Stories
- Five stocks we like better than Freenome
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Freenome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Freenome and related companies with MarketBeat.com's FREE daily email newsletter.
